Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. AMD
6. GOOG
7. CSX
8. IBM
9. KNX
10. LVS

Go back to Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
VERASTEM SHS (NASDAQ: VSTM) Delayed: 6.14 +0.25 (4.24%)
Previous Close $5.89    52 Week High $2.43 
Open $5.87    52 Week Low $1.05 
Day High $6.31    P/E N/A 
Day Low $5.75    EPS $-1.79 
Volume 1,677,651